ReviewJournal of pain research2026
Molecular Mechanisms and Therapeutic Targets for Pain Following Osteoporotic Vertebral Fractures.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic vertebral fractures (OVF) are among the most common fractures in older adults. They are strongly linked to severe pain, disability, and a reduced quality of life. Pain from OVFs often becomes chronic and differs from pain caused by fractures in normal bone. This review systematically summarizes the molecular mechanisms of OVF-related pain. It focuses on how changes in bone metabolism, inflammation, non-coding RNA regulation, and neural pathways affect each other. Major factors that drive the onset and persistence of OVF pain include increased osteoclast activity, abnormal Wnt/β-catenin signaling, inflammatory mediators, and neuropeptides. Recent studies also report new molecular targets that are closely related to OVF pain, such as TRPA1, WWP1, STK11, and specific microRNAs. Targeted treatments may improve pain control and function in patients with OVF. These include anti-neurosensitization drugs, anti-osteoporosis therapies, anti-inflammatory treatments, and neural modulators. More research is still needed to clarify these mechanisms and to develop safer, more effective, and more personalized treatments that improve outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.